NewsBenzingaAdagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer Benzinga 2026.10.28 11:05 (GMT+0) Open on Benzinga Other news ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart Canton Strategic Holdings Q3 Revenue of $3.05M, Net Loss Widens to $35.1M StablecoinX Q3 Revenue Reaches $478,000, Net Loss $100 Million
Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market
Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin
Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart